Clear All
785 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Q2041 Axicabtagene Ciloleucel Yescarta Up to 200 million Immunotherapy CAR-T CD19 No 2017 Jan 1, 2019 In Use
J9052 Carmustine (Accord) Carmustine 100mg Chemotherapy Alkylating Agent Nitrosurea No 2022 Dec 7, 2023 In Use
J9225 Histrelin Acetate Vantas 50 mg Hormonal Therapy GnRH Agonist No 2004 Jan 1, 2008 In Use
J9174 Docetaxel (beizray) Beizray 1mg Chemotherapy Antimitotic Agent Taxane No 2024 Jul 9, 2025 In Use
NA Sunitinib malate Sutent 50 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR,KIT, RET, CSF Yes 2006 In Use
J1447 Tbo-filgrastim Granix 1 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2015 Jan 1, 2016 In Use
C9476 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jul 1, 2016 In Use
NA Cervarix Human papillomavirus vaccine 20 mcg vaccine Ancillary Therapy Protective Agent HPV Vaccine No 2009 2016 In Use
Inovolisib Itovebi 3mg, 9mg Chemotherapy Enzyme Inhibitor PI3K⍺ Yes 2024 In Use
Q2057 Afamitresgene autoleucel Tecelra per therapeutic dose Immunotherapy T Cell Receptor (TCR) MAGE-A4 No 2024 Mar 26, 2025 In Use
Maribavir Livtencity 200mg Ancillary Therapy Miscellaneous Agent CMV Antiviral Yes 2021 In Use
N/A Zongertinib HERNEXEOS 60mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2025 In Use
J9056 Bendamustine hydrochloride (Vivimusta) Vivimusta 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2022 Jul 11, 2023 In Use
Q5158 Denosumab-bnht Bomyntra, Conexxence 1mg Immunotherapy Monoclonal Antibody RANKL No 2025 Sep 8, 2025 In Use
NA Imiquimod Aldara 5% Immunotherapy Immunomodulator Retinoic Acid Derivative No 1997 In Use
J9040 Bleomycin Bleomycin 15 units Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides No 1973 Jan 1, 1984 In Use
J9039 Blinatumomab Blincyto 1 mcg Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) No 2014 Jan 1, 2016 In Use
Q5159 Denosumab-dssb Ospomyv, Xbryk 1mg Immunotherapy Monoclonal Antibody RANKL No 2025 Sep 8, 2025 In Use
J1710 Hydrocortisone Sodium Phosphate Hydrocortone 50 mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid No 1960 2004 Jan 1, 1982 In Use
J9342 Thiotepa (not otherwise specified) Thiotepa 1mg Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine No 2001 Jul 9, 2025 In Use
Vorasidenib Voranigo 10mg,40mg Chemotherapy IDH Inhibitor IDH1, IDH2 Yes 2024 In Use
NA Enasidenib mesylate Idhifa 100 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
N/A Imlunestrant Inluriyo 200mg Hormonal Therapy Estrogen Receptor Antagonist ER⍺ Yes 2025 In Use
NA Nilotinib Tasigna 200 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
J8655 Netupitant/Palonosetron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist, Substance P/Neurokinin 1 Yes 2014 Jan 1, 2016 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.